Research from the O’Neal Comprehensive Cancer Center at UAB finds patients treated outside of NCCN Guidelines recommendations had significantly higher direct costs. A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer
News & Events
Academic Breast Cancer Consortium (ABRCC)
Explore Oncology Consortia
Criterium, Inc., a full-service CRO is pleased to announce the promotions of our two newest consortia directors, Drs D. Ross Camidge and Peter Kabos, both from the University of Colorado. Dr Camidge, Director for the ATOMIC Consortia for Thoracic and Lung Cancers, was recently promoted from his current position of Associate Professor, Division of Medical Oncology to "Professor with Tenure". Dr Kabos, Director for the ABRCC Consortia for Breast Cancer, was recently promoted from his current position of Assistant Professor, Division of Medical Oncology to "Associate Professor".
Criterium, Inc., a full service global CRO is pleased to announce the formation of its two new oncology consortia: ATOMIC (The Academic Thoracic Oncology Medical Investigator’s Consortium) focusing on Thoracic and Lung Cancers, and ABRCC (The Academic Breast Cancer Consortium), dedicated to Breast Cancer research.
Elena Shagisultanova, MD, PhD, Assistant Professor at the University of Colorado Denver Cancer Center and Lead Principal Investigator of the TULiP trial presented a trials-in-progress poster summarizing the study design for the ongoing trial in patients with hormone receptor positive and HER2-positive (HR+/HER2+) metastatic breast cancer.